Advanced or Metastatic Breast Cancer

Oncology
3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
1 program
1
Trastuzumab deruxtecanPhase 3ADC1 trial
Active Trials
NCT04494425Active Not Recruiting866Est. Jun 2026
Rain Oncology
Rain OncologyCA - Newark
1 program
1
MilademetanPhase 21 trial
Active Trials
NCT05932667TerminatedEst. Nov 2023
AN
Adlai NortyeNORTH BRUNSWICK, NJ
1 program
1
PelareorepPhase 11 trial
Active Trials
NCT05519059CompletedEst. May 2023
Pfizer
PfizerNEW YORK, NY
1 program
IbranceN/A2 trials
Active Trials
NCT06962969Not Yet Recruiting1,000Est. Nov 2025
NCT03159195Completed652Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoTrastuzumab deruxtecan
Rain OncologyMilademetan
Adlai NortyePelareorep
PfizerIbrance
PfizerIbrance

Clinical Trials (5)

Total enrollment: 2,518 patients across 5 trials

NCT04494425Daiichi SankyoTrastuzumab deruxtecan

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Start: Jul 2020Est. completion: Jun 2026866 patients
Phase 3Active Not Recruiting
NCT05932667Rain OncologyMilademetan

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Start: Oct 2023Est. completion: Nov 2023
Phase 2Terminated
NCT05519059Adlai NortyePelareorep

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Start: Oct 2021Est. completion: May 2023
Phase 1Completed
NCT06962969PfizerIbrance

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Start: Jun 2025Est. completion: Nov 20251,000 patients
N/ANot Yet Recruiting
NCT03159195PfizerIbrance

Ibrance Real World Insights

Start: Jun 2017Est. completion: Jun 2021652 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)